Key facts
- This page summarizes Lloyd Mitchell Segal's Form 4 filing for Repare Therapeutics Inc. (RPTX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 06 Mar 2025, 17:00.
Lloyd Mitchell Segal - 04 Mar 2025 Form 4 Insider Report for Repare Therapeutics Inc. (RPTX)
- Reporting relationship
- PRESIDENT AND CEO, Director
- Issuer ticker
- RPTX
- Reported as of
- 04 Mar 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Mar 2025, 17:00:12 UTC
- Prior SEC filing
- 01 Apr 2024
- Next SEC filing
- 14 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Steve Forte, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Lloyd Mitchell Segal filed Form 4 for Repare Therapeutics Inc. (RPTX) on 06 Mar 2025.
Change
- Previous filing in this sequence was filed on 01 Apr 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RPTX
transaction
Common Shares
Award
- Transaction value
- $0
- Shares
- +40,000
- Change %
- +38%
- Price
- $0.000000
- Shares after
- 145,573
- Date
- 04 Mar 2025
- Ownership
- Direct
- Footnotes
- F1, F2
RPTX
holding
Common Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 107,558
- Date
- 04 Mar 2025
- Ownership
- See footnote
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RPTX
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +237,000
- Change %
- Price
- $0.000000
- Shares after
- 237,000
- Date
- 04 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 237,000
- Exercise price
- $1.17
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Represents a restricted stock unit ("RSU") award. Thirty-three and one third percent (33 1/3%) of the RSUs shall vest on each of March 4, 2026, March 4, 2027 and March 4, 2028, subject to Reporting Person continuing to provide service through each such date.
Footnote F2
Includes 895 and 2,000 shares acquired on August 15, 2024 and February 15, 2025, respectively, under the Issuer's employee stock purchase plan.
Footnote F3
These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company.
Footnote F4
Twenty-five percent (25%) of the shares subject to the option shall vest on March 4, 2026, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.